-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On May 23, CDE's official website showed that Qilu Pharmaceutical's Class 1 new drugs QLH11906 tablets and QL1706 injection have obtained the implied license for clinical trials, and are intended to be used for advanced solid tumors and small cell lung canc.
Since the beginning of this year, Qilu Pharma has obtained 6 Class 1 new drugs for clinical approv.
Since the beginning of this year, Qilu Pharma has obtained 6 Class 1 new drugs for clinical approv.
The small-molecule chemical drug QLH11906 tablet was approved for clinical use for the first time, and the indication is advanced solid tumors with abnormal MAPK signaling pathway; the new indication of the macromolecular biological drug QL1706 injection (PD-1/CTLA-4 double antibody) was approved for clinical u.
For the treatment of extensive-stage small cell lung canc.
For the treatment of extensive-stage small cell lung canc.
Since the beginning of this year, Qilu Pharma has obtained 6 Class 1 new drugs for clinical approval, including QL1706 injection, QLH11906 tablets, QLS31904 for injection, QLS21908 for injection, QL1604 injection, and QLS31906 for injecti.
Qilu Pharmaceutical's Class 1 New Drugs Approved for Clinical Practice from 2022 to Present
Except for QLS21908 for injection, which is used for autoimmune diseases , the other class 1 new drugs belong to the field of tumor thera.
According to data from Min.
com, the domestic anti-tumor drug market has continued to expand in recent yea.
In 2021, the terminal sales in China's urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) will be close to 115 billion yu.
An increase of 11% year-on-ye.
com, the domestic anti-tumor drug market has continued to expand in recent yea.
In 2021, the terminal sales in China's urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) will be close to 115 billion yu.
An increase of 11% year-on-ye.
Sales of terminal antitumor drugs in Chinese public medical institutions (unit: ten thousand yuan)
Source: Min.
com China's public medical institutions terminal competition pattern
com China's public medical institutions terminal competition pattern
In recent years, Qilu Pharma has adhered to the innovation-driven strategy and continued to increase investment in scientific resear.
In 2021, Qilu Pharmaceutical's R&D investment will reach 32 billion yuan, and R&D investment will account for nearly 10% of sales reven.
At present, Qilu Pharmaceutical has 26 Class 1 new drugs in the clinical application and above stag.
In 2021, Qilu Pharmaceutical's R&D investment will reach 32 billion yuan, and R&D investment will account for nearly 10% of sales reven.
At present, Qilu Pharmaceutical has 26 Class 1 new drugs in the clinical application and above stag.
Data source: Minet database, NMPA
On May 23, CDE's official website showed that Qilu Pharmaceutical's Class 1 new drugs QLH11906 tablets and QL1706 injection have obtained the implied license for clinical trials, and are intended to be used for advanced solid tumors and small cell lung canc.
Since the beginning of this year, Qilu Pharma has obtained 6 Class 1 new drugs for clinical approv.
Since the beginning of this year, Qilu Pharma has obtained 6 Class 1 new drugs for clinical approv.
The small-molecule chemical drug QLH11906 tablet was approved for clinical use for the first time, and the indication is advanced solid tumors with abnormal MAPK signaling pathway; the new indication of the macromolecular biological drug QL1706 injection (PD-1/CTLA-4 double antibody) was approved for clinical u.
For the treatment of extensive-stage small cell lung canc.
For the treatment of extensive-stage small cell lung canc.
Since the beginning of this year, Qilu Pharma has obtained 6 Class 1 new drugs for clinical approval, including QL1706 injection, QLH11906 tablets, QLS31904 for injection, QLS21908 for injection, QL1604 injection, and QLS31906 for injecti.
Qilu Pharmaceutical's Class 1 New Drugs Approved for Clinical Practice from 2022 to Present
Except for QLS21908 for injection, which is used for autoimmune diseases , the other class 1 new drugs belong to the field of tumor thera.
According to data from Min.
com, the domestic anti-tumor drug market has continued to expand in recent yea.
In 2021, the terminal sales in China's urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) will be close to 115 billion yu.
An increase of 11% year-on-ye.
com, the domestic anti-tumor drug market has continued to expand in recent yea.
In 2021, the terminal sales in China's urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) will be close to 115 billion yu.
An increase of 11% year-on-ye.
Sales of terminal antitumor drugs in Chinese public medical institutions (unit: ten thousand yuan)
Source: Min.
com China's public medical institutions terminal competition pattern
com China's public medical institutions terminal competition pattern
In recent years, Qilu Pharma has adhered to the innovation-driven strategy and continued to increase investment in scientific resear.
In 2021, Qilu Pharmaceutical's R&D investment will reach 32 billion yuan, and R&D investment will account for nearly 10% of sales reven.
At present, Qilu Pharmaceutical has 26 Class 1 new drugs in the clinical application and above stag.
In 2021, Qilu Pharmaceutical's R&D investment will reach 32 billion yuan, and R&D investment will account for nearly 10% of sales reven.
At present, Qilu Pharmaceutical has 26 Class 1 new drugs in the clinical application and above stag.
Data source: Minet database, NMPA
On May 23, CDE's official website showed that Qilu Pharmaceutical's Class 1 new drugs QLH11906 tablets and QL1706 injection have obtained the implied license for clinical trials, and are intended to be used for advanced solid tumors and small cell lung canc.
Since the beginning of this year, Qilu Pharma has obtained 6 Class 1 new drugs for clinical approv.
Since the beginning of this year, Qilu Pharma has obtained 6 Class 1 new drugs for clinical approv.
The small-molecule chemical drug QLH11906 tablet was approved for clinical use for the first time, and the indication is advanced solid tumors with abnormal MAPK signaling pathway; the new indication of the macromolecular biological drug QL1706 injection (PD-1/CTLA-4 double antibody) was approved for clinical u.
For the treatment of extensive-stage small cell lung canc.
For the treatment of extensive-stage small cell lung canc.
Since the beginning of this year, Qilu Pharma has obtained 6 Class 1 new drugs for clinical approval, including QL1706 injection, QLH11906 tablets, QLS31904 for injection, QLS21908 for injection, QL1604 injection, and QLS31906 for injecti.
Qilu Pharmaceutical's Class 1 New Drugs Approved for Clinical Practice from 2022 to Present
Except for QLS21908 for injection, which is used for autoimmune diseases , the other class 1 new drugs belong to the field of tumor thera.
disease disease disease tumor tumor tumor According to data from Min.
com, the domestic anti-tumor drug market has continued to expand in recent yea.
In 2021, the terminal sales in China's urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) will be close to 115 billion yu.
An increase of 11% year-on-ye.
hospital hospital hospitalcom, the domestic anti-tumor drug market has continued to expand in recent yea.
In 2021, the terminal sales in China's urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) will be close to 115 billion yu.
An increase of 11% year-on-ye.
Sales of terminal antitumor drugs in Chinese public medical institutions (unit: ten thousand yuan)
Source: Min.
com China's public medical institutions terminal competition pattern
com China's public medical institutions terminal competition pattern
In recent years, Qilu Pharma has adhered to the innovation-driven strategy and continued to increase investment in scientific resear.
In 2021, Qilu Pharmaceutical's R&D investment will reach 32 billion yuan, and R&D investment will account for nearly 10% of sales reven.
At present, Qilu Pharmaceutical has 26 Class 1 new drugs in the clinical application and above stag.
In 2021, Qilu Pharmaceutical's R&D investment will reach 32 billion yuan, and R&D investment will account for nearly 10% of sales reven.
At present, Qilu Pharmaceutical has 26 Class 1 new drugs in the clinical application and above stag.
Data source: Minet database, NMPA
